Value
4.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 2.1 |
| Analyst target | 6.0 |
MIRM · Why this verdict
Why Mirum Pharmaceuticals (MIRM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Mirum Pharmaceuticals delivers 43% revenue growth, generates free cash flow despite a GAAP loss, and has entered a technical breakout — but two consecutive earnings misses and a historically elevated put/call ratio signal growing market skepticism about near-term execution, creating a binary outcome around the next catalyst.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The two most recent quarterly results both missed consensus estimates by wide margins — EPS surprises of approximately -206% and -309% in consecutive quarters — raising concern that guidance discipline has broken down or that the commercial ramp is more volatile than the headline revenue growth suggests. Earnings | The company beats consensus EPS estimates by more than 10% in the next reported quarter, breaking the two-quarter miss streak and restoring confidence in guidance reliability. | →Stable |
| CounterBoth recent misses followed two prior beats, and EPS estimates for a pre-profitability biotech are sensitive to research-and-development expense timing; the miss pattern may reflect analyst forecast error rather than operational deterioration. | ||
Despite reporting a GAAP net loss, the company generates a free cash flow margin of 29% and a yield of approximately 2.7%, confirming that cash generation is real and that non-cash charges are the primary driver of the accounting loss — a key distinction for assessing sustainability. Quality breakdown | Free cash flow margin stays above 20% for the next two reported quarters, confirming that positive cash generation is structural. | →Stable |
| CounterPositive free cash flow in a pre-profitability biotech may reflect deferred investment in commercial infrastructure; an acceleration in sales-force build-out or clinical spending could quickly reverse the cash position. | ||
Revenue is growing at 43% year-over-year, and the combined growth-plus-profitability score of 73 — well above the 40-point threshold used to assess growth company health — places the business in an elite tier among its peers. Growth breakdown | Revenue growth stays above 30% year-over-year for the next two consecutive quarters, confirming that commercial momentum is durable. | →Stable |
| CounterRevenue is channeled through a single specialty pharmacy, creating a structural single point of failure; any disruption in that distribution relationship could produce a sudden and severe step-down in reported sales. | ||
The stock has formed a golden cross, trades above all key moving averages, and shows rising volume accumulation — signals consistent with institutional demand establishing a technical breakout that historically attracts additional momentum buyers. Momentum breakdown | The stock continues to trade above its 200-day moving average without a cross below for at least the next six months. | →Stable |
| CounterBreakout patterns in high-short-interest biotechs are fragile; with 14% of the float sold short, a single negative catalyst could reverse price below the moving average quickly and trap momentum buyers. | ||
An options put/call ratio of 3.85 — a level indicating that bearish contracts significantly outweigh bullish ones — signals meaningful hedging or directional positioning by market participants who may be anticipating further earnings shortfalls. Risk breakdown | Put/call ratio falls below 2.0 over the next two months as earnings delivery improves and defensive positioning is unwound. | →Stable |
| CounterExtremely elevated put/call ratios can precede sharp short-covering rallies; if the next earnings result is a clean beat, the unwind of this bearish positioning could accelerate a rapid price move to the upside. | ||
The two most recent quarterly results both missed consensus estimates by wide margins — EPS surprises of approximately -206% and -309% in consecutive quarters — raising concern that guidance discipline has broken down or that the commercial ramp is more volatile than the headline revenue growth suggests.
→StableEarnings
- Expectation
- The company beats consensus EPS estimates by more than 10% in the next reported quarter, breaking the two-quarter miss streak and restoring confidence in guidance reliability.
CounterBoth recent misses followed two prior beats, and EPS estimates for a pre-profitability biotech are sensitive to research-and-development expense timing; the miss pattern may reflect analyst forecast error rather than operational deterioration.
Despite reporting a GAAP net loss, the company generates a free cash flow margin of 29% and a yield of approximately 2.7%, confirming that cash generation is real and that non-cash charges are the primary driver of the accounting loss — a key distinction for assessing sustainability.
→StableQuality breakdown
- Expectation
- Free cash flow margin stays above 20% for the next two reported quarters, confirming that positive cash generation is structural.
CounterPositive free cash flow in a pre-profitability biotech may reflect deferred investment in commercial infrastructure; an acceleration in sales-force build-out or clinical spending could quickly reverse the cash position.
Revenue is growing at 43% year-over-year, and the combined growth-plus-profitability score of 73 — well above the 40-point threshold used to assess growth company health — places the business in an elite tier among its peers.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 30% year-over-year for the next two consecutive quarters, confirming that commercial momentum is durable.
CounterRevenue is channeled through a single specialty pharmacy, creating a structural single point of failure; any disruption in that distribution relationship could produce a sudden and severe step-down in reported sales.
The stock has formed a golden cross, trades above all key moving averages, and shows rising volume accumulation — signals consistent with institutional demand establishing a technical breakout that historically attracts additional momentum buyers.
→StableMomentum breakdown
- Expectation
- The stock continues to trade above its 200-day moving average without a cross below for at least the next six months.
CounterBreakout patterns in high-short-interest biotechs are fragile; with 14% of the float sold short, a single negative catalyst could reverse price below the moving average quickly and trap momentum buyers.
An options put/call ratio of 3.85 — a level indicating that bearish contracts significantly outweigh bullish ones — signals meaningful hedging or directional positioning by market participants who may be anticipating further earnings shortfalls.
→StableRisk breakdown
- Expectation
- Put/call ratio falls below 2.0 over the next two months as earnings delivery improves and defensive positioning is unwound.
CounterExtremely elevated put/call ratios can precede sharp short-covering rallies; if the next earnings result is a clean beat, the unwind of this bearish positioning could accelerate a rapid price move to the upside.
Per-dimension breakdown
Quality
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 7.3 |
| FCF quality | 8.9 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 4.4 |
- ▸FCF-positive despite GAAP loss (FCF margin 29%, FCF yield 2.5%)
- ▸Rule of 40: 73 (elite)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 43% YoY
Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.2 |
- ▸Overbought (RSI 94)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 8.3 |
| erm sentiment | 5.2 |
- ▸Analyst upside: 26%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.2 |
- ▸Modest insider selling — $4,154,620 (0.061% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.3 |
| quality rank | 0.0 |
| growth rank | 6.3 |
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 9.8 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.9 |
| days to cover | 5.4 |
| volatility | 2.8 |
| put call | 10.0 |
| implied vol | 5.8 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 4.3 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:7.3>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (0)
none
Reward-to-Risk
0.67
Upside
+10.0%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.7<1.5@spot) reinforce the read. Current asymmetry R:R is 0.67 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Sentiment at 7.6, and Momentum at 7.3; the weakest are Peer rank at 2.6, Catalyst at 3.3, and Technical at 3.4. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.67 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue is growing at 43% year-over-year, and the combined growth-plus-profitability score of 73 — well above the 40-point threshold used to assess growth company health — places the business in an elite tier among its peers.
Trip ifRevenue growth falls below 25% year-over-year for 2 consecutive quarters.
- P2The stock has formed a golden cross, trades above all key moving averages, and shows rising volume accumulation — signals consistent with institutional demand establishing a technical breakout that historically attracts additional momentum buyers.
Trip ifStock falls below its 200-day moving average and closes below it for 10 consecutive trading sessions.
- P3The two most recent quarterly results both missed consensus estimates by wide margins — EPS surprises of approximately -206% and -309% in consecutive quarters — raising concern that guidance discipline has broken down or that the commercial ramp is more volatile than the headline revenue growth suggests.
Trip ifEPS surprise exceeds 10% in the next reported quarter.
- P4Despite reporting a GAAP net loss, the company generates a free cash flow margin of 29% and a yield of approximately 2.7%, confirming that cash generation is real and that non-cash charges are the primary driver of the accounting loss — a key distinction for assessing sustainability.
Trip ifFree cash flow margin falls below 10% for 2 consecutive quarters.
- P5An options put/call ratio of 3.85 — a level indicating that bearish contracts significantly outweigh bullish ones — signals meaningful hedging or directional positioning by market participants who may be anticipating further earnings shortfalls.
Trip ifPut/call ratio falls below 1.5 within 3 months.